Radionuclide Therapy Shows Promise in Advanced Prostate Cancer Treatment
• Radionuclide therapies are emerging as promising options for treating metastatic castration-resistant prostate cancer (mCRPC), especially after resistance to standard treatments.
• Lutetium-177 PSMA-617 (Lu-PSMA-617) has demonstrated overall survival benefits in mCRPC patients, leading to FDA and EMA approvals for PSMA-positive cases.
• Ongoing clinical trials are exploring Lu-PSMA-617 in earlier stages of prostate cancer and in combination with other therapies like androgen deprivation and immunotherapy.
• Targeted alpha therapy using Actinium-225 labeled PSMA ligands shows potential for improved outcomes, particularly in patients who do not respond to Lutetium-177 based treatments.
© Copyright 2025. All Rights Reserved by MedPath